[1]赵芳芳,郭 红,陈 嘉.LncRNA TUG1 在甲状腺癌组织中的表达及其对细胞增殖和迁移的影响[J].现代检验医学杂志,2020,35(06):42-47.[doi:doi:10.3969/j.issn.1671-7414.2020.06.011]
 ZHAO Fang-fang,GUO Hong,CHEN Jia.Expression of LncRNA TUG1 in Thyroid Carcinoma Tissues and Its Effect onCell Proliferation and Migration[J].Journal of Modern Laboratory Medicine,2020,35(06):42-47.[doi:doi:10.3969/j.issn.1671-7414.2020.06.011]
点击复制

LncRNA TUG1 在甲状腺癌组织中的表达及其对细胞增殖和迁移的影响()
分享到:

《现代检验医学杂志》[ISSN:/CN:]

卷:
第35卷
期数:
2020年06期
页码:
42-47
栏目:
论著
出版日期:
2020-12-30

文章信息/Info

Title:
Expression of LncRNA TUG1 in Thyroid Carcinoma Tissues and Its Effect onCell Proliferation and Migration
文章编号:
1671-7414(2020)06-042-06
作者:
赵芳芳郭 红陈 嘉
(汉中市人民医院内分泌科,陕西汉中 723000)
Author(s):
ZHAO Fang-fangGUO HongCHEN Jia
(Department of Endocrinology,the People’s Hospital of Hanzhong City,Shaanxi Hanzhong 723000,China)
关键词:
LncRNA TUG1甲状腺癌生物学行为
分类号:
R736.1;R730.43
DOI:
doi:10.3969/j.issn.1671-7414.2020.06.011
文献标志码:
A
摘要:
目的 检测 LncRNA TUG1 在甲状腺癌组织及细胞中的表达,探究其对细胞增殖和迁移的影响。方法 收集 2015年 1 月 ~2018 年 6 月在汉中市人民医院行手术治疗并经病理确诊的 36 例甲状腺癌患者癌组织标本及其相对应的正常癌旁甲状腺组织进行研究。采用 qRT-PCR 法检测甲状腺癌组织及 SW1736,FTC-133 细胞株中 LncRNA TUG1 表达水平。将shRNA 插入慢病毒质粒中构建 LncRNA TUG1 低表达质粒(LV-shTUG1)。采用 MTT 法、集落形成实验及 Transwell 实验检测敲降 LncRNA TUG1 表达对甲状腺癌细胞增殖和迁移的影响;采用蛋白印迹分析实验检测 LncRNA TUG1 对 EMT 相关蛋白E-cadherin和N-cadherin表达的影响。结果 与正常癌旁甲状腺组织相比,甲状腺癌组织中LncRNA TUG1高表达,差异有统计学意义(6.90±1.19 vs 1.51±1.02,t=20.634,P < 0.000)。与 Nthy-ori 3-1 细胞相比,FTC-133 细胞(1.00±0.09vs 4.61±0.15)和 SW1736 细胞(1.00±0.09 vs 2.59±0.23)中 LncRNA TUG1 水平明显升高,差异有统计学意义(t=35.744,P < 0.000;t=11.150,P < 0.000)。敲降 LncRNA TUG1 表达后, SW1736 细胞(1.31±0.19 vs 0.89±0.16)和 FTC-133细胞(2.17±0.09 vs 1.68±0.05)增殖能力较对照组明显降低,克隆形成数目明显减少,差异有统计学意义(t=2.929,P=0.021;t=8.243,P=0.001)。敲降 LncRNA TUG1 表达后,FTC-133 细胞迁移能力(1 675.2±64.2 vs 898.1±156.4)较对照组显著降低,差异有统计学意义(t=7.961,P=0.001)。敲降 LncRNA TUG1 表达后,与对照组相比,E-cadherin 表达量(0.74±0.06 vs 1.66±0.17)显著升高,N-cadherin表达量(1.27±0.18 vs 0.39±0. 07)显著降低,差异有统计学意义(t=8.839,P < 0.000;t=7.892,P=0.001)。结论 LncRNA TUG1 在甲状腺癌组织及细胞中高表达,促进甲状腺癌细胞增殖和迁移,可能通过促进 EMT 的形成进而促进甲状腺癌细胞的生物学行为。

参考文献/References:

[1] VANDERPUMP MARK P J. Epidemiology of thyroiddisorders:A comprehensive guide for the clinician[M].The Thyroid and Its Diseases,2019:75-85.
[2] 王卓颖,钱凯.晚期甲状腺癌新辅助治疗进展 [J].中国实用外科杂志 ,2019,39(3):275-279.WANG Zuoying,QIAN Kai. Progress of neoadjuvanttherapy for advanced thyroid cancer [J]. ChineseJournal of Applied surgery,2019,39(3):275-279.
[3] MAO Y,LIU R,ZHOU H,et al. Transcriptomeanalysis of miRNA-lncRNA-mRNA interactions inthe malignant transformation process of gastric cancerinitiation [J]. Cancer Gene Therapy, 2017, 24 (6):267-275.
[4] ZHU Shiyou,LI Wei,LIU Jingze, et al.Genome-scaledeletion screening of human long non-coding RNAsusing a paired-guide RNA CRISPR-Cas9 library [J].Nature Biotechnology,2016,34(12): 1279-1286.
[5] LI Zheng, SHEN Jianxiong, CHAN M T, et al. TUG1:a pivotal oncogenic long non-coding RNA of humancancers[J]. Cell Proliferation, 2016, 49(4): 471-475.
[6] NIU Yuchun,MA Feng,HUANG Weimei. Long non-coding RNA TUG1 is involved in cell growth andchemoresistance of small cell lung cancer by regulatingLIMK2b via EZH2[J]. Molecular cancer,2017,16(1) : 5.
[7] LIU Jia ,LIN Jieru ,LI Yingqi, et al. Prognostic role oflncRNA TUG1 for cancer outcome: Evidence from 840cancer patients[J].Oncotarget,2017,8(30):50051-50060.
[8] LIU Shankun , LIU Ying , LU Qiang,et al. ThelncRNA TUG1 promotes epithelial ovarian cancer cellproliferation and invasion via the WNT/β-cateninpathway [J]. Onco Targets Ther,2018,11:6845-6851.
[9] 张振,李芬.ceRNA 与肿瘤 [J].现代检验医学杂志,2016,31(4):128-130.ZHANG Zhen,LI Fen. ceRNA and tumor [J]. Journalof Modern Laboratory Medicine,2016,31(4):128-130.
[10] FOK E T,DAVIGNON L, FANUCCHI S,et al. ThelncRNA connection between cellular metabolismand epigenetics in trained immunity[J]. Frontiers inImmunology,2018, 9:3184.
[11] KOCH L. Functional genomics: Screening for lncRNAfunction[J]. Nature Reviews Genetics, 2017, 18(2): 70.
[12] ZHANG Pengfei, CAO Limian, FAN Pingsheng, etal. LncRNA-MIF, a c-Myc-activated long non-codingRNA, suppresses glycolysis by promoting Fbxw7-mediated c-Myc degradation[J]. EMBO Reports, 2016,17(8): 1204-1220.
[13] 白盈盈,朱光旭,潘兴华.长链非编码 RNA 对结直肠癌潜在诊断价值的研究进展 [J].现代检验医学杂志,2018,33(1):161-164.BAI Yingying,ZHU Guangxu,PAN Xinghua.Advances in the potential diagnostic value of long non-coding RNA in colorectal cancer [J]. Journal of ModernLaboratory Medicine,2016,33(1):161-164.
[14] XUE Mei,PANG Huan,LI Xu,et al. Long non-codingRNA urothelial cancer-associated 1 promotes bladdercancer cell migration and invasion by way of thehsa-miR-145-ZEB1/2-FSCN1 pathway[J]. Cancerscience,2016,107(1): 18-27.
[15] CHEN Xuemei,HAN Hongyu,LI Yuqi,et al.Upregulation of long noncoding RNA HOTTIPpromotes metastasis of esophageal squamouscell carcinoma via induction of EMT[J].Oncotarget,2016,7(51): 84480-84485.
[16] SUN Ming, NIE Fengqi, WANG Yunfei, et al.LncRNA HOXA11-AS promotes proliferation andinvasion of gastric cancer by scaffolding the chromatinmodification factors PRC2, LSD1, and DNMT1[J].Cancer Research, 2016, 76(21): 6299-6310.
[17] CAO Jiaqing, HAN Xinyou, QI Xin, et al. TUG1promotes osteosarcoma tumorigenesis by upregulatingEZH2 expression via miR-144-3p[J]. InternationalJournal of Oncology, 2017, 51(4): 1115-1123.
[18] XU Youtao,WANG Jie,QIU Mantang,et al. Upregulationof the long noncoding RNA TUG1 promotesproliferation and migration of esophageal squamouscell carcinoma[J].Tumour Biology,2015,36(3): 1643-1651.
[19] ILIEV R, KLEINOVA R, JURACEK J, et al.Overexpression of long non-coding RNA TUG1predicts poor prognosis and promotes cancer cellproliferation and migration in high-grade muscle-invasive bladder cancer[J]. Tumour Biology, 2016,37(10): 13385-13390.
[20] LI Jun,AN Gang,ZHANG Meng,et al. Long non-codingRNA TUG1 acts as a miR-26a sponge in human gliomacells[J]. Biochemical and Biophysical Research Comm-unications,2016,477(4):743-748.
[21] WANG Liang, ZHAO Zhenxian, FENG Weidong, etal. Long non-coding RNA TUG1 promotes colorectalcancer metastasis via EMT pathway[J]. Oncotarget,2016, 7(32): 51713-51719.
[22] LIN Y H,WU Menghan,HUANG Yahui,et al. Taurineup-regulated gene 1 functions as a master regulator tocoordinate glycolysis and metastasis in hepatocellularcarcinoma[J]. Hepatology (Baltimore, Md.),2018,67(1):188-203.
[23] HAN Xiufu,YANG Yanming,SUN Yongjie,et al.LncRNA TUG1 affects cell viability by regulatingglycolysis in osteosarcoma cells[J]. Gene, 2018, 674:87-92.
[24] 徐苏娟,付子毅,刘丝雨,等.lncRNA TUG1 对卵巢癌细胞 OVCAR3 的增殖迁移及能量代谢的影响[J].临床肿瘤学杂志 ,2019,24(1):26-31.XU Sujuan,FU Ziyi,LIU Siyu,et al. Effects oflncRNA TUG1 on proliferation, migration and energymetabolism of OVCAR3 cells[J]. Chinese ClinicalOncology,2019,24(1):26-31.
[25] BOROUGHS L K, DEBERARDINIS R J. Metabolicpathways promoting cancer cell survival and growth[J].Nature Cell Biology, 2015, 17(4): 351-359.
[26] DANHIER P, BA?SKI P, PAYEN V L, et al. Cancermetabolism in space and time: Beyond the Warburgeffect[J]. Biochimica et Biophysica Acta-Bioenergetics,2017, 1858(8): 556-572.

相似文献/References:

[1]彭继英a,杨红杰b,石晓欣a,等.细针穿刺细胞学检查在甲状腺癌碘-131 治疗后复发诊断中的应用价值[J].现代检验医学杂志,2020,35(01):127.[doi:10.3969/j.issn.1671-7414.2020.01.033]
 PENG Ji-yinga,YANG Hong-jieb,SHI Xiao-xina,et al.Application Value of Fine Needle Aspiration Cytology in Recurrence Diagnosis of Thyroid Cancer after Iodine-131 Treatment[J].Journal of Modern Laboratory Medicine,2020,35(06):127.[doi:10.3969/j.issn.1671-7414.2020.01.033]
[2]仲亚东,孔德桐,马伯敏.甲状腺癌患者组织及手术前后血清中NR3C2 和ZEB1 表达水平及其与预后价值研究[J].现代检验医学杂志,2023,38(04):94.[doi:10.3969/j.issn.1671-7414.2023.04.017]
 ZHONG Yadong,KONG Detong,MA Bomin.Study on the Expression Level of NR3C2 and ZEB1 in Thyroid Cancer Tissue and Serum of Patients before and after Surgery and Their Prognostic Value[J].Journal of Modern Laboratory Medicine,2023,38(06):94.[doi:10.3969/j.issn.1671-7414.2023.04.017]
[3]谈玖婷,傅聿明,刘 婧,等.甲状腺癌组织中DCBLD2 和MAP4K3 的表达及与临床病理特征及预后的关系[J].现代检验医学杂志,2024,39(02):34.[doi:10.3969/j.issn.1671-7414.2024.02.007]
 TAN Jiuting,FU Yuming,LIU Jing,et al.Expression of DCBLD2 and MAP4K3 in Thyroid Cancer Tissue and Their Relationship with Clinico-pathological Features and Prognosis[J].Journal of Modern Laboratory Medicine,2024,39(06):34.[doi:10.3969/j.issn.1671-7414.2024.02.007]
[4]张廷华a,胡友元b,袁 博.miR-100-5p 对甲状腺癌细胞增殖与凋亡调控作用的实验研究[J].现代检验医学杂志,2024,39(04):56.[doi:10.3969/j.issn.1671-7414.2024.04.011]
 ZHANG Tinghuaa,HU Youyuanb,YUAN Bo.Experimental Study on the Regulatory Effects of miR-100-5p on Proliferation and Apoptosis of Thyroid Cancer Cells[J].Journal of Modern Laboratory Medicine,2024,39(06):56.[doi:10.3969/j.issn.1671-7414.2024.04.011]

更新日期/Last Update: 2020-12-20